Fulcrum Therapeutics, Inc.
FULC evidence brief
What we can confirm
- BioSniper Score:
- 8.3 / 10
- Market Cap:
- $289.9M
- Lead Asset:
- losmapimod (Phase 3)
What it means
What to watch
Prepared research question
What matters most for FULC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FULC
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases, with its lead candidate pociredir in Phase 1b trials for sickle cell disease.
Key risk: Clinical-stage pipeline risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials for Fulcrum Therapeutics, Inc..
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases, with its lead candidate pociredir in Phase 1b trials for sickle cell disease.
- Fulcrum is a clinical-stage biopharmaceutical company focused on genetically defined rare diseases with high unmet medical need [sec · filed 2026-04-30].
- Lead candidate pociredir (formerly FTX-6058) is in a Phase 1b PIONEER trial for sickle cell disease; 12 mg dose cohort showed mean absolute HbF increase from 7.6% to 16.2% at 12 weeks [sec · filed 2026-04-30].
- Cash, cash equivalents, and marketable securities were $200.6 million as of Q3 2025, with a cash runway into 2028 [news · published 2025-10-29].
- Accumulated deficit was $554.3 million as of June 30, 2025 [sec_mda · as of 2025-07-29].
- The company decided not to advance its bone marrow failure syndromes program and terminated a license agreement with a collaborator in April 2026 [sec_mda · as of 2026-04-27].
What works
- Pociredir demonstrated early progression toward pan-cellular HbF induction and improvements in hemolysis and anemia markers in the 12 mg dose cohort [sec · filed 2026-04-30].
- Cash runway extends into 2028, providing financial flexibility for ongoing trials [news · published 2025-10-29].
- The company has a proprietary discovery platform that identified pociredir and is exploring complementary mechanisms for SCD [sec_mda · as of 2026-04-27].
What to weigh
- Fulcrum has incurred significant operating losses since inception and expects expenses to increase as it advances pociredir and other programs [sec_mda · as of 2025-07-29].
- The company terminated its bone marrow failure syndromes program and a license agreement, indicating pipeline contraction [sec_mda · as of 2026-04-27].
- Pociredir is still in early-stage clinical trials (Phase 1b), with no approved products or late-stage data yet [sec · filed 2026-04-30].
From the filings
Quoted directly from source documents.
Pociredir increased mean absolute HbF from 7.6% to 16.2% at 12 weeks in the 12 mg dose cohort.
“Mean absolute fetal hemoglobin, or HbF, increased by 8.6% at 12 weeks of treatment with pociredir, increasing from a baseline of 7.6% to 16.2%.”
SEC filings · April 30, 2026
Cash position as of Q3 2025 was $200.6 million with runway into 2028.
“Ended Q3 2025 with $200.6 million in cash, cash equivalents, and marketable securities; cash runway into 2028”
News · October 29, 2025
Accumulated deficit was $554.3 million as of June 30, 2025.
“As of June 30, 2025, we had an accumulated deficit of $554.3 million.”
SEC MD&A · July 29, 2025
Fulcrum decided not to advance its bone marrow failure syndromes program and terminated a license agreement in April 2026.
“Based on results from IND-enabling studies, we have decided not to advance our program for bone marrow failure syndromes into clinical development and will focus our resources on advancing pociredir and our core benign hematology programs. In April 2026, we provided notice to terminate our license agreement with CA”
SEC MD&A · April 27, 2026
Risks & what to watch (3)›
Key risks
- Clinical-stage pipeline risk — Pociredir is in Phase 1b; no approved products or late-stage data exist, so clinical failure is a key risk [sec · filed 2026-04-30].
- Significant accumulated deficit — Accumulated deficit of $554.3M as of June 2025; ongoing losses expected to increase [sec_mda · as of 2025-07-29].
- Pipeline contraction — Termination of bone marrow failure program and a license agreement reduces pipeline breadth [sec_mda · as of 2026-04-27].
What to watch
- Data from the 20 mg dose cohort of the PIONEER trial, expected by year-end 2025 [news · published 2025-10-29].
- Initiation and results of the open-label extension trial for pociredir [sec_mda · as of 2025-10-29].
- Updates on preclinical programs for complementary HbF induction mechanisms and FTX-6274 [sec_mda · as of 2026-04-27].
- Cash burn rate and any future financing needs given the $200.6M cash position [news · published 2025-10-29].
Sources: News · SEC filings · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run Fulcrum Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Fulcrum Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.04 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
6 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 12.1%
- Days to cover
- 8.1
- Shares short
- 7,967,121
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FULC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Fulcrum Therapeutics, Inc.?
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases, with its lead candidate pociredir in Phase 1b trials for sickle cell disease.
What is Fulcrum Therapeutics, Inc.'s lead drug candidate?
Fulcrum Therapeutics, Inc.'s most advanced tracked candidate is losmapimod (Phase 3) for Facioscapulohumeral Muscular Dystrophy 1; Facioscapulohumeral Muscular Dystrophy (FSHD).
Who is the CEO of Fulcrum Therapeutics, Inc.?
Mr. Alexander C. Sapir is the chief executive officer of Fulcrum Therapeutics, Inc. (FULC).
Where is Fulcrum Therapeutics, Inc. headquartered?
Fulcrum Therapeutics, Inc. (FULC) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Fulcrum Therapeutics, Inc. focus on?
Fulcrum Therapeutics, Inc. develops therapies across Oncology, Rare Disease, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.